SMARCB1 and neoplasm: Moreover, once-daily treatment with CP-C27 led to marked suppression of tumor growth in another SMARCB1-deficient JMU-RTK-2 xenograft model (Fig. 7a, b), but not in a SMARCB1-proficient H460 xenograft model (Fig. 7c, d).